» Articles » PMID: 36807417

The Advent of Immune Stimulating CAFs in Cancer

Overview
Journal Nat Rev Cancer
Specialty Oncology
Date 2023 Feb 22
PMID 36807417
Authors
Affiliations
Soon will be listed here.
Abstract

The theory that cancer-associated fibroblasts (CAFs) are immunosuppressive cells has prevailed throughout the past decade. However, recent high-throughput, high-resolution mesenchyme-directed single-cell studies have harnessed computational advances to functionally characterize cell states, highlighting the existence of immunostimulatory CAFs. Our group and others have uncovered and experimentally substantiated key functions of cancer antigen-presenting CAFs in T cell immunity, both in vitro and in vivo, refuting the conventional assumption that CAFs impede adaptive immune rejection of tumours. In this Perspective, I unify the follicular and non-follicular, non-endothelial stroma of tumours under the 'peripheral adaptive immune mesenchyme' framework and position subsets of CAFs as direct positive regulators of the adaptive immune system. Building on the understanding of cancer antigen presentation by CAFs and the second touch hypothesis, which postulates that full T cell polarization requires interaction with antigen-presenting cells in the non-lymphoid tissue where the antigen resides, I re-design the 'cancer-immunity cycle' to incorporate intratumoural activation of cancer-specific CD4 T cells. Lastly, a road map to therapeutic harnessing of immunostimulatory CAF states is proposed.

Citing Articles

Antigen-presenting cancer associated fibroblasts enhance antitumor immunity and predict immunotherapy response.

Song J, Wei R, Liu C, Zhao Z, Liu X, Wang Y Nat Commun. 2025; 16(1):2175.

PMID: 40038297 PMC: 11880398. DOI: 10.1038/s41467-025-57465-7.


ITGA4 as a potential prognostic and immunotherapeutic biomarker in human cancer and its clinical significance in gastric cancer: an integrated analysis and validation.

Zhang J, Wang G, Liu J, Tang F, Wang S, Li Y Front Oncol. 2025; 15:1513622.

PMID: 40012546 PMC: 11860100. DOI: 10.3389/fonc.2025.1513622.


KRT7 promotes pancreatic cancer metastasis by remodeling the extracellular matrix niche through FGF2-fibroblast crosstalk.

Jiang Y, Liao C, Lai J, Peng Y, Chen Q, Zheng X Sci Rep. 2025; 15(1):6951.

PMID: 40011455 PMC: 11865440. DOI: 10.1038/s41598-024-84129-1.


Spatial transcriptomics reveals prognostically LYZ fibroblasts and colocalization with FN1 macrophages in diffuse large B-cell lymphoma.

Dai L, Lou N, Huang L, Li L, Tang L, Shi Y Cancer Immunol Immunother. 2025; 74(4):123.

PMID: 39998673 PMC: 11861843. DOI: 10.1007/s00262-025-03968-7.


A novel HVEM-Fc recombinant protein for lung cancer immunotherapy.

Yao Y, Li B, Wang J, Chen C, Gao W, Li C J Exp Clin Cancer Res. 2025; 44(1):62.

PMID: 39979981 PMC: 11841141. DOI: 10.1186/s13046-025-03324-8.


References
1.
Davidson S, Coles M, Thomas T, Kollias G, Ludewig B, Turley S . Fibroblasts as immune regulators in infection, inflammation and cancer. Nat Rev Immunol. 2021; 21(11):704-717. DOI: 10.1038/s41577-021-00540-z. View

2.
Koliaraki V, Prados A, Armaka M, Kollias G . The mesenchymal context in inflammation, immunity and cancer. Nat Immunol. 2020; 21(9):974-982. DOI: 10.1038/s41590-020-0741-2. View

3.
Croft A, Campos J, Jansen K, Turner J, Marshall J, Attar M . Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature. 2019; 570(7760):246-251. PMC: 6690841. DOI: 10.1038/s41586-019-1263-7. View

4.
Biffi G, Tuveson D . Diversity and Biology of Cancer-Associated Fibroblasts. Physiol Rev. 2020; 101(1):147-176. PMC: 7864232. DOI: 10.1152/physrev.00048.2019. View

5.
Sahai E, Astsaturov I, Cukierman E, DeNardo D, Egeblad M, Evans R . A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020; 20(3):174-186. PMC: 7046529. DOI: 10.1038/s41568-019-0238-1. View